Revolution Medicines, Inc. (RVMDW) stock
RVMDWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as RVMD
$9.81+0.18 (+1.82%)
Close on Oct 30, 2026Market cap $41.00BP/E –Yield –
Revolution Medicines operating margin
Operating margin is operating income as a percentage of revenue.
Revolution Medicines's operating margin for the twelve months ending Sep 30, 2024 was -88031.9%. For fiscal 2023 it was -4207.1%, against -730.0% the year before. The highest annual figure on record is -108.2% in fiscal 2019.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | -4207.1% | −3477.1 |
| FY2022 | Dec 31, 2022 | -730.0% | −90.3 |
| FY2021 | Dec 31, 2021 | -639.7% | −382.2 |
| FY2020 | Dec 31, 2020 | -257.5% | −149.4 |
| FY2019 | Dec 31, 2019 | -108.2% | +91.8 |
| FY2018 | Dec 31, 2018 | -200.0% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q4 FY2023 | Dec 31, 2023 | -24256.5% | −21976.0 |
| Q2 FY2023 | Jun 30, 2023 | -2845.1% | −2164.0 |
| Q1 FY2023 | Mar 31, 2023 | -1071.5% | −306.8 |
| Q4 FY2022 | Dec 31, 2022 | -402.5% | +156.8 |
| Q3 FY2022 | Sep 30, 2022 | -2280.5% | +2548.1 |
| Q2 FY2022 | Jun 30, 2022 | -681.1% | −169.1 |
| Q1 FY2022 | Mar 31, 2022 | -764.7% | −395.6 |
| Q4 FY2021 | Dec 31, 2021 | -559.3% | −169.9 |
| Q3 FY2021 | Sep 30, 2021 | -4828.6% | −4611.0 |
| Q2 FY2021 | Jun 30, 2021 | -512.0% | −232.9 |
| Q1 FY2021 | Mar 31, 2021 | -369.1% | −186.5 |
| Q4 FY2020 | Dec 31, 2020 | -389.4% | −227.6 |
| Q3 FY2020 | Sep 30, 2020 | -217.6% | −109.2 |
| Q2 FY2020 | Jun 30, 2020 | -279.1% | −193.1 |
| Q1 FY2020 | Mar 31, 2020 | -182.6% | −103.3 |
| Q4 FY2019 | Dec 31, 2019 | -161.8% | – |
| Q3 FY2019 | Sep 30, 2019 | -108.4% | – |
| Q2 FY2019 | Jun 30, 2019 | -86.0% | – |
| Q1 FY2019 | Mar 31, 2019 | -79.3% | – |